What 5 Analyst Ratings Have To Say About Exelixis
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…
Where Exelixis Stands With Analysts
Analysts have provided the following ratings for Exelixis (NASDAQ:EXEL) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
Exelixis’ Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Exelixis Provides Update On Phase 3 CONTACT-01 Trial Evaluating Cabozantinib In Combination With Atezolizumab In Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With Immunotherapy And Chemotherapy
Exelixis, Inc. (NASDAQ:EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®)
Morgan Stanley Maintains Equal-Weight on Exelixis, Lowers Price Target to $22
Morgan Stanley analyst Jeffrey Hung maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $23 to $22.
EF Hutton Initiates Coverage On Exelixis with Buy Rating, Announces Price Target of $28
EF Hutton analyst Michael King initiates coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and announces Price Target of $28.
JMP Securities Initiates Coverage On Exelixis with Market Outperform Rating, Announces Price Target of $26
JMP Securities analyst Silvan Tuerkcan initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Outperform rating and announces Price Target of $26.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
